Articles related to PRECISION MEDICINE

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.

The multidisciplinary guidelines introduce blood-based biomarkers as key diagnostic tools, potentially reducing unnecessary CT scans while improving outcome predictions.

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.